misperception is suspected (strong recommendation, high-quality evidence). Cognitive behavioural therapy for insomnia is recommended as the first-line treatment for chronic insomnia in adults of any age (strong recommendation, high-quality evidence). A pharmacological intervention can be offered if cognitive behavioural therapy for insomnia is not sufficiently effective or not available. Benzodiazepines, benzodiazepine receptor agonists and some antidepressants are effective in the shortterm treatment of insomnia (≤4 weeks; weak recommendation, moderate-quality evidence). Antihistamines, antipsychotics, melatonin and phytotherapeutics are not recommended for insomnia treatment (strong to weak recommendations, low-to very-low-quality evidence). Light therapy and exercise need to be further evaluated to judge their usefulness in the treatment of insomnia (weak recommendation, lowquality evidence). Complementary and alternative treatments (e.g. homeopathy, acupuncture) are not recommended for insomnia treatment (weak recommendation, very-low-quality evidence).
GUIDELINE REPORT AND M ETHODS
This European guideline for the diagnosis and treatment of insomnia was developed on the basis of the guideline for insomnia by the German Sleep Society (Riemann et al., 2017) , and has been modified and extended through the involvement of experts from various European countries and the European Insomnia Network under the umbrella of the European Sleep Research Society (ESRS). A more detailed version of this guideline's report can be found in the supplemental material.
The guideline focuses on insomnia, defined as difficulties initiating or maintaining sleep, or early morning awakening associated with impaired daytime functioning, for example, reduced cognitive performance, fatigue or mood disturbances. Thus, the target population of this guideline comprises patients suffering from insomnia as defined by ICD-10/ ICSD-3. This includes all subtypes of insomnia, for example, non-organic insomnia and insomnia co-morbid with somatic or mental disorders. The guideline addresses adult patients (≥18 years). The literature on insomnia in children and adolescents was not reviewed. This guideline reviews the available literature with a special focus on the situation in Europe. The guideline is meant for physicians and clinical psychologists/psychotherapists who diagnose and treat patients with insomnia.
Computer-based searches using PubMed (www.ncbi.nlm. nih.gov/pubmed/) and the Cochrane Library (www.cochrane library.com) were conducted with the following keywords: (psychotherapy OR sleep hygiene OR relaxation OR mindfulness OR behaviour therapy OR cognitive therapy OR cognitive behavioural therapy OR stimulus control OR sleep restriction OR placebo OR benzodiazepine OR benzodiazepine receptor agonist OR sedating antidepressant OR antipsychotic OR neuroleptic OR antihistamine OR herbal therapy OR phytotherapy OR melatonin OR complementary alternative therapy OR homeopathy) AND insomnia (search filter set to meta-analysis). Furthermore, all issues of the journal 'Sleep Medicine Reviews' (until June 2016) were screened for additional relevant publications, and the search was expanded through identifying further publications from references in the screened full-texts. The search included studies conducted from January 1966 to June 2016. Studies were required to be written in English to be included. The first author conducted the literature search, screened titles and abstracts, and examined the full texts with the help of the third and last authors. Concerning the translation of effect sizes (Cohen's d) into text form, effect sizes <0.4 were defined as a small effect; effect sizes >0.4-0.8 as a good effect; effect sizes >0.8 as a very good effect.
The GRADE (Grading of Recommendations Assessment, Development and Evaluation; Atkins et al., 2004; Guyatt et al., 2008) system was used to grade the evidence and inform recommendations. The published evidence was rated as high quality if the examined meta-analyses suggested it to be very unlikely that further research would change our confidence in the estimate of an observed effect. In contrast, the verdict low quality was given when the examined metaanalyses suggested that any estimate of effect is uncertain. Table S1 shows the classification system for the quality of evidence according to Guyatt et al. (2008) in detail. Two grades of recommendations were used: 'strong' and 'weak'. The transformation of levels of evidence into grades of recommendation was based on a consensus being reached between the authors. 1986). Given recent developments in the DSM-5 (2013) and ICSD-3 (2014) , we will use the terms insomnia and insomnia disorder interchangeably throughout this guideline. Instead of the previously used dichotomy primary versus secondary insomnia, we will follow the concept of comorbidity.
Several research groups have suggested aetiological and pathophysiological models of insomnia (Espie, 2002; Espie et al., 2006; Harvey, 2002; Levenson et al., 2015; Morin, 1993; Riemann et al., , 2015 . Most of these are explicitly or implicitly based on the so-called '3P' model of insomnia by Spielman et al. (1987) , which postulates that predisposing, precipitating and perpetuating factors are involved in the aetiology of insomnia. For example, genetic influences (Palagini et al., 2014) or personality characteristics like neuroticism or maladaptive perfectionism are seen as predisposing factors.
Acute stressors, for example, stress at work or interpersonal conflicts, usually trigger acute insomnia. Acute insomnia is very common and often a transient phenomenon, which is relieved after cessation of the stressor (Ellis et al., 2012a; Espie, 2002) . Chronic stress exposure may also be seen as an underlying cause for chronic insomnia. In many cases, perpetuating factors have to come into play during the transition from acute to chronic insomnia. Spielman et al. (1987) suggested that maladaptive coping strategies are perpetuating factors, for example, prolonged time in bed or napping in order to catch up on lost sleep. While these behaviours may appear reasonable, they can reduce sleep pressure and may lead to chronic insomnia in the long run. Additionally, Espie et al. (2006) have emphasized the development of a maladaptive focus upon sleep in patients with insomnia, whereby sleep-related attentional biases and direct attempts to control sleep disturb the two-process bioregulation of sleep (Borb ely, 1982; Borb ely and Achermann, 1999) , interfering with the expected default recovery to normal sleep, following episodic stress.
The hyperarousal model of insomnia postulates that increased arousal levels in the cognitive, emotional and physiological domains represent both predisposing 'and' perpetuating factors (Perlis et al., 1997; Riemann et al., 2010 Riemann et al., , 2015 . Central to this model are results showing that patients with insomnia have increased power in fast electroencephalographic (EEG) frequencies during non-rapid eye movement sleep. This might also be reflected by an increased cyclic alternating pattern rate (Chouvarda et al., 2012) . An increased frequency of microarousals during rapid eye movement (REM) sleep, which contributes to the perception of parts of REM sleep as wakefulness, has also been observed in patients with insomnia, relative to normal sleepers (Feige et al., 2013; . Neurobiologically, hyperarousal may be driven by a dominance of arousal-generating brain areas relative to sleep-inducing brain areas (Saper et al., 2005) .
Cognitive models of insomnia stress the relevance of worry and rumination in the development and maintenance of insomnia (Harvey, 2002) . Moreover, Baglioni et al. (2010) have emphasized that patients with insomnia have an increased emotional reactivity, which may also be of aetiological relevance.
Circadian factors are important in a subgroup of individuals, for example in those who undertake shift work or in blind patients, where desynchronization of the sleep-wake pattern and the circadian phase contributes to sleep initiation and sleep maintenance difficulties. This also applies to some cases of sleep-onset insomnia in adolescents/young adults, whereby a circadian phase delay may be the underlying factor, and to elderly patients with early awakening, whereby a phase advance may play a role (Abbott et al., 2016) .
Definition of insomnia -diagnostic classification systems
In most European countries, use of the International Classification of Diseases (ICD-10, 1992 ) is mandatory for physicians and clinical psychologists/psychotherapists in order to get reimbursed through health insurance. For the diagnosis of insomnia, the diagnostic categories 'Non-organic insomnia' (F51.0) and 'Disorders of initiating and maintaining sleep (insomnias)' (G47.0) are relevant. The definition for nonorganic insomnia is presented in Table 1 .
The diagnosis of 'non-organic insomnia', according to ICD-10, is based solely on the subjective experience of afflicted individuals. No quantitative criteria for sleep-onset latency, sleep duration, or the frequency, or duration, of nocturnal awakenings is required. The term 'non-organic insomnia' refers to the fact that this sleep disorder does not have a specific recognizable somatic disorder at its core. However, the use of this term has been discussed critically over the last few years in light of documented neurobiological alterations in patients with insomnia. DSM-5 (2013) has removed the distinction between primary and secondary insomnia. This distinction was aimed at differentiating 'pure' independent insomnia from 'secondary' insomnia, i.e. insomnia being related to or even hypothetically being caused by another somatic/mental disorder. Instead, the new umbrella category 'insomnia disorder' was introduced, which is also used in the third Table 1 Diagnostic criteria for non-organic insomnia (F51.0) according to • Disturbance of sleep onset or sleep maintenance, or poor sleep quality.
• Sleep disturbances occur at least three times a week over a period of 1 month.
• The afflicted individuals focus extremely on their sleep disorder (especially during the night) and worry about the negative consequences of insomnia.
• The insufficient sleep duration and quality is coupled with a high degree of suffering or impairs daily activities. ICSD-3; AASM, 2014) . The decision to remove the distinction between primary and secondary insomnia was based on an NIH conference on insomnia in 2005 (National Institutes of Health, 2005) , with the lack of evidence that treating the primary disorder would relieve insomnia accordingly, for example in cases of insomnia associated with depression, being the main reason for this change. The definition of insomnia within the ICSD-3 largely follows that of the DSM-5. Table 2 shows the diagnostic criteria for insomnia according to the ICSD-3. In order to receive the diagnosis, there must be a disturbance of nocturnal sleep (criterion A) and related daytime impairment (criterion B). Furthermore, the sleep disorder has to occur at least 3 nights a week for a period of 3 months to be diagnosed as a clinically relevant disorder. If diagnostic criteria are fulfilled co-morbid with a mental or somatic disorder, both disorders are diagnosed.
As already mentioned, acute insomnia is very common and does not need a specific treatment in all cases (Ellis et al., 2012b) . Chronic insomnia, instead, needs to be treated. The definitions for chronicity are, however, varying. ICD-10 requires a minimum duration of 1 month, whereas the ICSD-3 specifies 3 months. The authors of this guideline endorse the use of ICSD-3 for diagnostic purposes, and expect the development of ICD-11 will most likely follow the conceptual innovations of ICSD-3.
Diagnostic procedure
The recommended procedure for the diagnostic management of insomnia disorder, and its co-morbidities, is shown in Table 3 .
A medical and psychiatric/psychological anamnesis is mandatory, and has to be tailored to the clinical picture of the patient and his/her symptomatology. With respect to the assessment of medical disorders, it needs to be borne in mind that some somatic causes of insomnia can be specifically treated, for example hyperthyroidism. However, even in the case of a clear somatic cause, many patients with insomnia develop a psychophysiological vicious cycle of insomnia, which includes rumination, worry about the consequences of poor sleep and increased physiological tension. These processes can be successfully treated in these co-morbid cases of insomnia.
Similar considerations should be made for substance use (e.g. alcohol/caffeine), which is important to evaluate in patients with insomnia. In particular, alcohol consumption is a common maladaptive self-treatment strategy in patients with insomnia, and can contribute to sleep-maintenance difficulties. Thus, alcohol consumption should be actively evaluated and considered during treatment planning. Furthermore, many medications can interfere with sleep. Therefore, the use, dosage and timing of medication should also be evaluated.
Mental disorders, especially depression, bipolar disorder or psychosis are also frequently accompanied by sleep-onset or sleep-maintenance difficulties or early morning awakening. A recent meta-analysis (Baglioni et al., 2016) showed that disturbances of sleep continuity (prolonged sleep latency, increased frequency of nocturnal awakenings, prolonged periods of wakefulness after sleep onset) occur transdiagnostically in almost all mental disorders. Patients with chronic insomnia often suffer from a co-morbid mental disorder, which they do not spontaneously report. This may be due to the fact that it is easier for some patients to talk about sleep than to talk about emotional distress. Thus, the presence of mental disorders should also be actively examined. Tiredness/fatigue also occurs in many mental or neurodegenerative disorders. Sleepiness (presumably experienced as a consequence of sleep loss) is usually not a symptom of insomnia per se, but may be due to an accumulation of sleep loss in these patients. As such, tiredness/fatigue and sleepiness should also be assessed. Table 4 summarizes the major somatic and mental comorbidities of insomnia.
The diagnostic procedure should also include a clinical interview consisting of a thorough sleep history (to assess sleep hygiene behaviour, sleep habits, sleep environmentincluding co-sleeping arrangements, work schedules, circadian factors and indications of other sleep disorders, e.g. restless legs syndrome, sleep apnea, circadian sleep-wake disorder, etc.). The consensus sleep diary (Carney et al., 2012) , for 7-14 days, is also strongly recommended. Moreover, the Pittsburgh Sleep Quality Index (PSQI) can be used to assess subjective sleep during the previous month (Buysse et al., 1989) . The PSQI, however, is not a specific instrument for diagnosing insomnia and should not be used for that purpose. The Insomnia Severity Index (ISI) has been developed to assess the severity of the disorder, and has also been shown to be a reliable and valid instrument to detect patients with insomnia (Bastien et al., 2001) . In addition, the Bergen Insomnia Scale (Pallesen et al., 2008) and the Sleep Condition Indicator (Espie et al., 2012) have promising psychometric properties. An overview of the available scales for assessing sleep, and sleep disorders, is provided by Shahid et al. (2012) . Furthermore, if indicated, actigraphy or polysomnography should be considered.
A meta-analysis of polysomnographic studies showed that patients with insomnia have a significantly reduced total sleep time, significantly prolonged sleep-onset latencies, and an increased number of nocturnal awakenings and amount of time awake during the night (Baglioni et al., 2014) . Furthermore, slow-wave sleep and REM sleep percentages are reduced compared with good sleepers. However, the differences were not very pronounced, for example, total sleep time was reduced by about 25 min. In contrast, subjective total sleep time is reduced by about 2 h in patients with insomnia compared with good sleepers (Feige et al., 2008) . This has led to the use of the terms 'pseudoinsomnia', 'sleep state misperception' or 'paradoxical insomnia'. Many experts argue that polysomnography is not helpful in the assessment of insomnia because it does not correlate with the subjective perceptions of patients. However, we suggest polysomnography may have an additional diagnostic value 'because' it does not correlate with subjective measures and thus may deliver information not inherent in the subjective patient report. In addition, objective measures are mandatory to diagnose potential co-morbid disorders (e.g. PLMD = Periodic Leg Movement Disorder, sleep apnea), which are common. Sleep apnea may have a complex relationship with insomnia, thus being more than a mere co-morbidity (Sweetman et al., 2017) . Several studies suggest that the polysomnographically determined microstructure of sleep is altered in insomnia, with increases in fast frequency power and in the number of microarousals. These phenomena are partly independent of the subjective experience of sleep , and may become relevant for treatment decisions in the future (see 'Outlook for the future'). Another recent discovery concerns differences between insomnia with, and without, an objective short sleep duration (Fernandez-Mendoza, 2017; Vgontzas et al., 2013) . It is hypothesized that insomnia with polysomnographically documented short sleep duration has primarily biological roots and would thus respond better to biological treatments. If this hypothesis turns out to be true, polysomnography may become even more important in the diagnostic procedure for insomnia.
Epidemiology
Approximately 6% of the adults in industrialized countries suffer from chronic insomnia as a disorder (for overview, see Ohayon, 2002) , with a clear-cut preponderance of females compared with males (Zhang and Wing, 2006) and an agerelated increase in prevalence rates. More recent data (e.g. from Norway, the UK and Germany) indicate an increase in the prevalence of insomnia, to about 10% of the population, in recent years (Calem et al., 2012; Marschall et al., 2017; Pallesen et al., 2014) . Moreover, it appears that the use of hypnotic agents has also increased significantly over a 10-year period (e.g. from 7% to 11% in Norway; Pallesen et al., 2001 Pallesen et al., , 2014 . Table 5 shows epidemiological data on the prevalence of insomnia, as a disorder, in 10 European countries (no such data are available for insomnia, on the disorder level, for the other European countries). Table 5 demonstrates that the prevalence of insomnia varies largely from one European country to the other. This may be, in part, due to differences in methodological quality between studies. At present the prevalence of insomnia, as a disorder, in Europe, seems to vary from a minimum of 5.7% in Germany to a maximum of 19% in France. There is only one comprehensive epidemiological study (Van de Straat and Bracke, 2015 ) that employed a cross-national approach and studied sleep problems across 16 European countries, but only in older adults. This study did not specifically include questions to derive insomnia diagnoses, just a single item measure of sleep problems. This study showed that the prevalence rate for this type of sleep problem varies from a minimum of 16.6% in Denmark to a maximum of 31.2% in Poland. Our literature search and the study by van de Straat and Bracke suggest an urgent need for Pan-European cross-sectional studies to better understand the size of the problem in Europe, also with respect to co-morbidities.
Studies in general practice or medical specialty settings deliver substantially higher prevalence rates: data from general practice in Germany (Wittchen et al., 2001) indicate that one-fifth of the patients consulting a GP suffer from insomnia; whereas in Norway more than 50% of GP patients have insomnia (Bjorvatn et al., 2017) .
In terms of the persistence of insomnia, there is very little information from Europe. However, Morin et al. (2009a) provided data on the natural course of insomnia in Canada, and showed that approximately 70% of the patients show persistent symptoms over the course of 1 year. In this study, 46% of those suffering from insomnia showed persistent symptoms over the course of 3 years. The prevalence of hypnotic usage, i.e. usage of benzodiazepines (BZ) and benzodiazepine receptor agonists (BZRAs), varies largely from one European country to the other. A UK study reported an increase in hypnotic usage from 0.4% to 0.8% in the general population from 1993 to 2000 -the data remained stable from 2000 to 2007 (Calem et al., 2012) . A German study described the prevalence of having taken a hypnotic, at least once, increased from 4.7% to 9.2% from 2009 to 2016 (Marschall et al., 2017) . In general, it is not clear how many patients with insomnia in Europe regularly take hypnotics -further research is necessary to determine the exact scale of this issue.
Health risks
Several meta-analyses show that insomnia is a significant risk factor for cardiovascular diseases (Li et al., 2014; Meng et al., 2013; Sofi et al., 2014) . Specifically, insomnia is a risk factor for arterial hypertension, myocardial infarction and chronic heart failure (Laugsand et al., 2011 (Laugsand et al., , 2014a Palagini et al., 2013) . In addition, Anothaisintawee et al. (2015) showed that insomnia is a risk factor for type 2 diabetes.
Besides insomnia itself, there is evidence suggesting that short sleep duration (sleeping less than 6 h on average) is a risk factor for obesity, type 2 diabetes, hypertension and cardiovascular diseases Buxton and Marcelli, 2010; Cappuccio et al., 2010; Faraut et al., 2012; Patel and Hu, 2008) . Consequently, short sleep duration also increases mortality (Liu et al., 2017) . However, the association between a short sleep duration and insomnia is not yet fully understood.
Neurological disorders are frequently co-morbid with insomnia (Mayer et al., 2011) , and insomnia may play a role in the development of cognitive impairment (Yaffe et al., 2014) . In addition, one cross-sectional study suggests a relationship between impaired sleep quality and cortical atrophy in older adults (Sexton et al., 2014) . More recent work points to a general involvement of insomnia in the development of neurodegenerative disease, especially dementia (Osorio et al., 2011) . Bassetti et al. (2015) stress the bi-directional nature of the relationship between insomnia and brain disorders.
Significant evidence has been gathered with respect to the relationship between insomnia and mental disorders (Riemann and Voderholzer, 2003) . In a meta-analysis, Baglioni et al. (2011) showed that people with insomnia have an increased risk for the development of major depressive disorder (odds ratio 2.1), which may also lead to early retirement (Paunio et al., 2015) . Similar relationships have been documented for insomnia complaints and suicide ideation, suicide attempts and completed suicides (Malik et al., 2014; Pigeon et al., 2012) .
Large epidemiological studies have also demonstrated that insomnia is a risk factor for sick leave, an increased number of accidents in the work place (Laugsand et al., 2014b; Sivertsen et al., 2009a,b) and motor-vehicle accidents (L eger et al., 2014) .
Costs of insomnia
The question of the direct and indirect costs of insomnia has been dealt with in several large, well-designed, studies (Daley et al., 2009; L eger and Bayon, 2010; Ozminkowski et al., 2007) . Of particular relevance to Europe, the costs of several brain disorders in Europe were compared in 2010 (Gustavsson et al., 2011) . This study ranked sleep disorders ninth among all neuropsychiatric disorders with respect to direct and indirect costs. An average total sum (costs) of €790 per year, per patient, was calculated. These overall costs were based on individual costs calculated against the estimated prevalence of insomnia, ranging from 6% to 12%, in the European population (Wittchen et al., 2011) . Concerning so-called DALYs (disability-adjusted life-years), a figure of 10.3/10 000 individuals was given for females, and 8.4/10 000 individuals for malesranking ninth among all neuropsychiatric disorders studied. According to WHO data, insomnia ranked 11th in the list of most important brain disorders with respect to global burden (Collins et al., 2011) . Thus, it can be concluded that insomnia represents a high financial burden to European healthcare systems, either through direct costs, i.e. costs for medication or psychotherapeutic treatment, or indirect costs, for example, due to sick leave or early retirement.
Treatment of insomnia
In the presence of co-morbidities, clinical judgement should decide whether the insomnia or the co-morbid condition is treated first, or whether both are treated at the same time. Of note, the grading and recommendations of all the treatment options outlined in this section are collectively summarized in Table 15 .
Cognitive behavioural therapy for insomnia (CBT-I) and other psychotherapeutic approaches
Cognitive behavioural therapy for insomnia usually consists of psychoeducation/sleep hygiene, relaxation training, stimulus control therapy, sleep restriction therapy and cognitive therapy (Riemann and Perlis, 2009 ). Usually, CBT-I is applied face to face (either on an individual basis or in a group format) by a trained clinician in four-eight sessions. A number of manuals have been published in different languages (Dutch: Verbeek and van de Laar, 2014; English: Morin and Espie, 2004; Perlis et al., 2005; French: Goulet et al., 2013; German: Hertenstein et al., 2015; Spiegelhalder et al., 2011; Italian: Devoto and Violani, 2009; Norwegian: Bjorvatn, 2013; Portuguese: Paiva, 2008; and Slovakian: Backhaus and Riemann, 2003) .
Psychoeducation/sleep hygiene. In the context of CBT-I, psychoeducation typically includes the so-called 'sleep ª 2017 European Sleep Research Society hygiene rules' about health practices (e.g. clockwatching, physical exercise, substance use) and environmental factors (e.g. light, noise, temperature) that may promote or disrupt sleep (Hauri, 1991) . Furthermore, psychoeducation includes basic information about normal sleep and age-related changes in sleep patterns.
Relaxation therapy. Relaxation therapy includes clinical procedures aimed at reducing somatic tension (e.g. progressive muscle relaxation, autogenic training) or intrusive thoughts at bedtime (e.g. imagery training, meditation).
Behavioural strategies (sleep restriction, stimulus control). Sleep restriction therapy is a method designed to curtail the time in bed to the actual amount of sleep being achieved (Spielman et al., 1987) . For example, if a patient with insomnia reports sleeping 6.5 h per night on average, the initial recommended sleep window (the time from lights out to final arising time) would be restricted to 6.5 h (with a minimum sleep window of 4-6 h being advised, even when the average sleep time is lower; Kyle et al., 2015) . On a weekly basis, adjustments to this sleep window are made. Time in bed is either increased by 15-30 min (when sleep efficiency is >85-90%), kept stable or decreased by 15-30 min (when sleep efficiency is <80%), until an optimal sleep duration is reached. It is strongly recommended that sleep diaries be used to estimate sleep time, both before starting sleep restriction therapy and also during follow-ups. Stimulus control therapy is a set of behavioural instructions designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep-wake schedule (Bootzin, 1972) : (1) go to bed only when sleepy; (2) get out of bed when unable to sleep; (3) use the bed/bedroom only for sleep and sex (e.g. no reading, no watching TV); (4) arise at the same time every morning; (5) do not nap during the day.
Cognitive therapy. Cognitive strategies are psychological methods designed to identify, challenge and change misconceptions about sleep and faulty beliefs about insomnia and its perceived daytime consequences (Morin and Espie, 2004) . These strategies include methods aimed at reducing or preventing excessive monitoring of, and worrying about, insomnia and its correlates or consequences.
Other psychotherapeutic approaches. Other psychotherapeutic approaches that have been empirically investigated include mindfulness-based treatments and hypnotherapy. Mindfulness-based treatments are rooted in Buddhist philosophy, and include stress reduction techniques and cognitive elements (Crane et al., 2017) . Hypnotherapy is also conceived as a mind-body intervention bearing similarities to meditation techniques. Hypnotherapy consists of verbal suggestions by the therapist, which are supposed to elicit subconscious changes (Facco, 2017; Terhune et al., 2017) .
Grading of the evidence. There are 15 published metaanalyses on the efficacy of CBT-I (Table 6 ). These comprise meta-analyses of CBT-I for 'primary' insomnia as well as meta-analyses of CBT-I for co-morbid insomnia. In the latter, it was shown that CBT-I has a positive impact on both insomnia complaints and co-morbid symptoms.
The first five meta-analyses (Irwin et al., 2006; Montgomery and Dennis, 2004; Morin et al., 1994; Murtagh and Greenwood, 1995; Pallesen et al., 1998) and the metaanalysis provided by Trauer et al. (2015) dealt with the efficacy of CBT-I, or its components, in patients with primary insomnia. All these meta-analyses demonstrated good efficacy for CBT-I (according to our translated definition of effect sizes) on sleep-related outcome parameters, and a good stability of the results at follow-up assessments. Belleville et al. (2011) showed that CBT-I has a small to moderate effect on anxiety levels in patients with or without clinically relevant co-morbid anxiety. Miller et al. (2014) investigated one component of CBT-I, i.e. sleep restriction therapy. This meta-analysis was based on only four studies, but showed good efficacy for sleep restriction therapy. Group CBT-I was investigated by Koffel et al. (2015) . This metaanalysis demonstrated a good efficacy for group format; however, only eight original studies could be included. The most recent meta-analyses addressed CBT-I for co-morbid insomnia, i.e. insomnia in the context of mental or somatic disorders. Geiger-Brown et al. (2015) and Wu et al. (2015a, b) dealt with a variety of co-morbid conditions, whereas Ho et al. (2016) , Johnson et al. (2016) and Tang et al. (2015) specifically investigated insomnia in the context of posttraumatic stress disorder, cancer and chronic pain. These metaanalyses showed that co-morbid insomnia also responds well to CBT-I. Of particular importance, CBT-I, though focusing exclusively on sleep, also had good effects on the co-morbid conditions.
There is also evidence supporting the efficacy of brief versions of CBT-I, for example, using two face-to-face sessions and two telephone calls or just one session for acute insomnia (Ellis et al., 2015) . There are also other forms of application, for example, group CBT-I courses delivered by nurses (Espie et al., 2007) . Table 7 shows meta-analyses on the efficacy of self-help and internet-based CBT-I. These six meta-analyses focus on self-help CBT-I approaches (Ho et al., 2015; Van Straten and Cuijpers, 2009 ), or internet-based CBT-I, for example, the programmes 'sleep healthy using the internet' (SHUTi; Ritterband et al., 2009) or SLEEPIO (Espie et al., 2012) . The four meta-analyses on internet-based CBT-I showed good treatment efficacy; however, the efficacy was lower than for face-to-face CBT-I. One of these meta-analyses investigated the effects of internet-based CBT-I on anxiety and depression levels, and showed small to moderate effects (Ye et al., 2015) . A recent large randomized controlled trial also suggested that internet-based CBT-I reduced subclinical depression levels and may thus be used for the prevention of depression (Christensen et al., 2016) . Moreover, Thiart et al. (2016) investigated the health economic effects of computerized CBT-I (cCBT-I), concluding that it was associated with an 87% probability of being more effective than treatment as usual.
ª 2017 European Sleep Research Society Two meta-analyses have been published comparing CBT-I with pharmacotherapy. Smith et al. (2002) compared pharmacological studies using BZ or BZRAs with psychotherapeutic studies, and concluded that both options are comparably effective in the short term. Mitchell et al. (2012) analysed studies that directly compared CBT-I with pharmacotherapy; only five studies fulfilled the inclusion criteria. Based on this evidence, the authors concluded that CBT-I and hypnotics have comparable efficacy in the short term, and that CBT-I is superior in the long term.
An interesting question is whether a combination of CBT-I with medication has synergistic effects. Two randomized controlled trials addressed this issue using CBT-I with temazepam or zolpidem (Morin et al., 1999 (Morin et al., , 2009b . In the acute treatment phase, the combination of CBT-I and pharmacotherapy appears to be slightly superior compared with either treatment alone. However, during maintenance treatment, discontinuation of pharmacotherapy appears to be more favourable (Morin et al., 2009b) . The authors also present their data in terms of response/remission criteria. According to this data evaluation, CBT-I alone led to a positive treatment response in 60% and remission in 40% of cases. These outcomes were stable at follow-ups or even improved (remission at 6 months follow-up: 67.8%).
With respect to mindfulness-based treatments and hypnotherapy, three meta-analyses have been published (Gong et al., 2016; Kanen et al., 2015; Lam et al., 2015) . The metaanalyses on mindfulness-based treatments noted moderate to good effects (Gong et al., 2016; Kanen et al., 2015) on sleep parameters. Hypnotherapy had a positive impact on sleep-onset latency; however, the overall quality of the studies included was poor. Thus, these treatments may be promising but the evidence is less convincing than it is for CBT-I.
As will be discussed in more detail in the section on hypnotics, the placebo effect needs to be noted in the context of the efficacy of psychotherapy. In comparison with pharmacological research, placebo-controlled studies are more difficult to conduct in psychotherapy research, as therapists can usually not be blinded towards 'sham' therapies. Thus, due to this methodological difficulty, psychotherapy studies may overestimate treatment efficacy.
The aforementioned evidence suggests that CBT-I is recommended as first-line treatment for chronic insomnia in adults of any age (strong recommendation, high-quality evidence; see Tables 6, 7 and 15). (Table 8) .
Before summarizing the efficacy of these different pharmacological substances, we present four meta-analyses on the placebo effects in this condition ( Table 9 ). The three newest of these meta-analyses concluded that there are significant placebo effects in clinical trials of pharmacological treatments for insomnia. Most notably, Winkler and Rief (2015) analysed 32 studies with 3969 participants, and found that more than 60% of the response to medication (in most studies BZ and BZRAs) was also observed with placebo. This finding held true for both subjectively and polysomnographically measured sleep parameters.
Grading of the evidence. Table 10 summarizes the metaanalyses on the efficacy of BZ and BZRAs in the treatment of insomnia. These meta-analyses clearly show that BZ and BZRAs are effective in the short-term treatment (≤4 weeks) of insomnia. Pillai et al. (2017) analysed data from one randomized controlled trial with BZRAs according to definitions of treatment response/remission, and observed positive treatment responses in 76.7% of cases and remissions in 47.7% of participants. Table 11 (upper panel) summarizes the meta-analyses on the efficacy of antidepressants in the treatment of insomnia. It should be noted that dosages for antidepressants to treat insomnia are usually much lower than the recommended doses for depression. Only a few randomized controlled trials have evaluated the efficacy of these mostly sedating antidepressants. The authors of the first two meta-analyses concluded that the efficacy of sedating antidepressants is weaker than that for BZ/BZRAs. However, McCleery et al.
(2014) described positive effects of trazodone for sleep disorders co-morbid with Alzheimer's disease. The metaanalysis by Yeung et al. (2015) dealt exclusively with lowdose doxepin, and showed that there are significant effects on subjective and polysomnographic parameters in the short term.
There are no meta-analyses on the efficacy of antihistamines in insomnia, but one systematic review concluded that antihistamines have only a small to moderate efficacy in the treatment of insomnia and that tolerance to these substances develops quickly (Vande Griend and Anderson, 2012) . Of note, many sedating antidepressants (Table 11 , upper panel) probably exert their hypnotic effect through the histaminergic system.
There are no meta-analyses on the efficacy of antipsychotics in insomnia, but four related systematic reviews exist. Monti and Monti (2004; Monti et al., 2017) and Cohrs (2008) concluded that sedating antipsychotics increase total sleep time and the amount of slow-wave sleep in patients with schizophrenia. However, Anderson and Vande Griend (2014) and Thompson et al. (2016) conclude that the evidence on quetiapine is insufficient to recommend its use in the treatment of insomnia, in the absence of psychiatric disorders, particularly in light of its potential side-effects. Table 11 (lower panel) summarizes the meta-analyses on the efficacy of phytotherapeutics in the treatment of insomnia. The authors of these publications came unanimously to the conclusion that the methodological quality of the studies included was poor and further studies are warranted. The meta-analyses did not show a clinically relevant efficacy of the investigated substances. A meta-analysis of studies investigating Chinese herbal medicine (CHM) concluded that CHM is superior to placebo with respect to its effect on subjective sleep parameters and equally effective as BZ. However, the authors of the meta-analysis emphasize the poor quality of the original studies, which cannot be independently assessed by the authors of this guideline Table 12 summarizes meta-analyses on the efficacy of melatonin (including mainly fast-release preparations, but also ramelteon and prolonged-release formulations) in the treatment of insomnia. These meta-analyses do not provide a uniform picture concerning the efficacy of melatonin and the melatonin receptor agonist ramelteon. Buscemi et al. (2005) and Ferracioli-Oda et al. (2013) reported that melatonin reduces sleep-onset latency, which was also demonstrated for ramelteon (Liu and Wang, 2012) . Kuriyama et al. (2014) also found significant positive effects of melatonin on sleep-onset latency and sleep quality. However, the effects were small from a clinical point of view. Some of the original studies also investigated undesired side-effects and concluded that melatonin is a safe drug.
The aforementioned evidence suggests that BZ and BZRAs may be used in the short term if the first-line treatment (CBT-I) is ineffective or unavailable (high-quality evidence). Some sedating antidepressants too may be used for short-term treatment (moderate-quality evidence).
Further, antihistamines and antipsychotics are not recommended for the treatment of insomnia (strong recommendation -low-to very-low-quality evidence), and melatonin and phytotherapy are not recommended for insomnia (weak recommendation -low-quality evidence; Tables 8-12 and  15) .
Light therapy and exercise
Light exposure has been used as a powerful experimental tool in animal research on sleep-wake and circadian rhythms, with clear-cut effects being observed on a variety of biological outcome variables. In humans, light therapy has been used as a treatment for seasonal affective disorders and circadian rhythm disorders with supposedly good clinical efficacy (Huck et al., 2014) . Exercise doubtlessly has positive effects on psychological and physical health, and many studies show that regular exercise reduces mortality (Hupin et al., 2015) . Of particular importance for the current guideline, both light therapy and exercise have also been suggested to be efficacious in patients with insomnia. Kredlow et al. (2015) investigated the effects of different exercise regimes on sleep in good and poor sleepers. While moderately positive effects were shown on several sleep parameters, it has to be stressed that most original studies did not focus on clinically relevant insomnia. Given the fact that both light therapy and exercise are supported by extensive basic and public health research, further studies should be devoted to delineate their effects in patients with insomnia. The aforementioned evidence suggests that light therapy and/or exercise may be useful adjuvant therapies for insomnia (weak recommendation -low-quality evidence; Table 15 ).
Complementary and alternative medicine
In the area of complementary and alternative medicine, several treatments for insomnia have been suggested, including acupuncture, acupressure, aromatherapy, foot reflexology, homeopathy, meditative movement therapies, moxibustion, music therapy and yoga.
Grading of the evidence. Table 13 summarizes metaanalyses and systematic reviews on the efficacy of complementary and alternative treatments for insomnia. Overall, the studies underlying this evidence are methodologically poor and thus difficult to evaluate. There is some evidence suggesting that acupuncture is effective (Cao et al., 2009; Cheuk et al., 2012; Lan et al., 2015; Sarris and Byrne, 2011) . However, evaluation of the studies on this topic is difficult for the authors of this guideline because most of the original articles are published in Chinese. The authors of all of the above-mentioned meta-analyses have stressed caution due to the quality of the original studies. There is no evidence supporting the efficacy of aromatherapy or homeopathy. Three meta-analyses on music therapy (Jespersen et al., 2015; de Niet et al., 2009; Wang et al., 2016) exist and suggest a potential positive effect of this treatment. However, the methodological quality of these studies is questionable. A similar picture arises for foot reflexology, moxibustion and meditative movement therapies, including yoga. These treatments may have potential; however, the poor quality of many of the original studies (as noted by the authors of the meta-analyses) makes it difficult to reach clear conclusions.
The aforementioned evidence suggests that complementary and alternative treatments for insomnia are not recommended (weak recommendation -very-low-quality evidence; Tables 13 and 15 ).
Long-term treatment of insomnia with hypnotics
The pharmacological literature summarized above dealt with the short-term treatment of insomnia (≤4 weeks). The rationale for this is that the hypnotics available are exclusively indicated, and approved, only for short-term treatment in most European countries. Arguably, however, the longterm treatment of insomnia using hypnotics is clinically relevant because insomnia typically returns following withdrawal. Table 14 summarizes the results of studies that investigated the long-term use of hypnotics (for at least 12 weeks) for insomnia.
These long-term studies show that the efficacy of hypnotics may remain stable over longer periods of administration. However, in some studies the effects decreased over time. Moreover, it has to be noted that some of the investigated substances, i.e. eszopiclone, zolpidem SR, ramelteon and suvorexant, are not available in Europe. To circumvent the possible risks of chronic hypnotic usage, such as dependence and rebound insomnia, some authors have suggested intermittent use especially for BZ and BZRAs (Parrino et al., 2008) . However, there are no metaanalyses examining the effects of intermittent use of hypnotics on insomnia. An alternative solution, suggested by Voshaar et al. (2006) , is to employ counselling interventions including, where necessary, CBT-I during discontinuation. In general, hypnotic discontinuation should be based on slowly tapering off medication, supporting patients during this sometimes difficult period with counselling, CBT-I or, if necessary, alternative medications (e.g. sedating antidepressants).
Based upon the evidence, BZ and BZRAs are not recommended in the longer-term treatment of insomnia (strong recommendation -low-quality evidence; Tables 14  and 15 ).
Risks and side-effects of insomnia treatment
The side-effects of CBT-I have not been thoroughly investigated yet. However, Kyle et al. (2011 Kyle et al. ( , 2014 stress that sleep restriction, as one component of CBT-I, leads to transient increases in somnolence and fatigue and (Hoffmann, 2013; Kapil et al., 2014; Uhlenhuth et al., 1999) . These sideeffects are often aggravated by multi-pharmacy, especially in older adults. It is undisputed that BZ and BZRA have the potential for tolerance and dependency. However, there are little data available on the number of patients who will become dependent when taking BZ or BZRA for a certain period of time. Hallfors and Saxe (1993) showed in one metaanalysis that substances with short half-lives induce dependency more quickly. Moreover, the acute cognitive effects of zopiclone, zolpidem, zaleplone and eszopiclone were • It is recommended to actively ask for medication and other substance use (alcohol, caffeine, nicotine, illegal drugs), which may disturb sleep (strong recommendation, high-quality evidence).
• Sleep diaries or actigraphy can be used in case of clinical suspicion of irregular sleep-wake schedules or circadian rhythm disorders (strong recommendation, high-quality evidence), and actigraphy can be used to assess quantitative sleep parameters (weak recommendation, high-quality evidence).
• Polysomnography is recommended when there is clinical suspicion of other sleep disorders, like periodic limb movement disorder, sleep apnea or narcolepsy, treatment-resistant insomnia, insomnia in occupational at-risk groups, or suspicion of a large discrepancy between subjectively experienced and polysomnographically measured sleep (strong recommendation, high-quality evidence).
Treatment
In the presence of co-morbidities, clinical judgement should decide whether insomnia or the co-morbid condition is treated first, or whether both are treated at the same time.CBT-I CBT-I is recommended as first-line treatment for chronic insomnia in adults of any age (strong recommendation, high-quality evidence). Pharmacological interventions A pharmacological intervention can be offered if CBT-I is not effective or not available.
BZ and BZRA
• BZ and BZRA are effective in the short-term treatment of insomnia (≤4 weeks; high-quality evidence).
• The newer BZRA are equally effective as BZ (moderate-quality evidence).
• BZ/BZRA with shorter half-lives may have less side-effects concerning sedation in the morning (moderate-quality evidence).
• Long-term treatment of insomnia with BZ or BZRA is not generally recommended because of a lack of evidence and possible side-effects/risks (strong recommendation, low-quality evidence). In patients using medication on a daily basis, reduction to intermittent dosing is strongly recommended (strong recommendation, low-quality evidence). Sedating antidepressants • Sedating antidepressants are effective in the short-term treatment of insomnia; contraindications have to be carefully considered (moderate-quality evidence). Long-term treatment of insomnia with sedating antidepressants is not generally recommended because of a lack of evidence and possible side-effects/risks (strong recommendation, low-quality evidence). Antihistaminics • Because of insufficient evidence, antihistaminics are not recommended for insomnia treatment (strong recommendation, low-quality evidence). Antipsychotics • Because of insufficient evidence and in light of their side-effects, antipsychotics are not recommended for insomnia treatment (strong recommendation, very low-quality evidence). Melatonin • Melatonin is not generally recommended for the treatment of insomnia because of low efficacy (weak recommendation, low-quality evidence). Phytotherapy • Valerian and other phytotherapeutics are not recommended for the treatment of insomnia because of poor evidence (weak recommendation, low-quality evidence). Light therapy and exercise • Light therapy and exercise regimes may be useful as adjunct therapies (weak recommendation, low-quality evidence).
Complementary and alternative medicine • Acupuncture, aromatherapy, foot reflexology, homeopathy, meditative movement, moxibustion and yoga are not recommended for the treatment of insomnia because of poor evidence (weak recommendation, very low-quality evidence).
BZ, benzodiazepine; BZRA, benzodiazepine receptor agonist; CBT-I, cognitive behavioural therapy for insomnia; CT, Computed Tomography; ECG, electrocardiogram; EEG, electroencephalogram; MRT, Magnetic Resonance Tomography.
ª 2017 European Sleep Research Society examined in one meta-analysis by Stranks and Crowe (2014) . On the basis of their findings, they suggest zolpidem and zopiclone have significant negative effects on next-day cognitive performance. Other notable results with respect to the negative impact of BZRAs include: Tom et al. (2016) , who reported that use of zolpidem was associated with greater risk of hip fracture and traumatic brain injury than eszopiclone; Sun et al. (2016a) who demonstrated a significant relationship between zolpidem use and suicide attempts, as well as completed suicides; and Joya et al.
who showed an increased risk for minor infections with the use of eszopiclone and zolpidem, compared with placebo. In terms of cognitive effects after withdrawal from long-term BZ use, one meta-analysis showed that negative effects might last up to 6 months (Barker et al., 2004) . In light of the evidence, Glass et al. (2005) conclude that the undesired side-effects outweighed the benefits of BZ/BZRA use in the elderly >60 years.
Three meta-analyses have been published on the effects of BZ and BZRAs on driving abilities. Verster et al. (2006) showed that BZ and zopiclone lead to impaired driving abilities. Further, Rapoport et al. (2009) and Dassanayake et al. (2011) showed a significant correlation between BZ use and accidents. A combination of alcohol use and BZ intake further increases the risk for accidents. Of note, sedating antidepressants also increase the risk of accidents.
It has been discussed, albeit controversially, whether BZ and BZRA increase the risk for mortality. In terms of the existing evidence, Palmaro et al. (2015) conducted an analysis of two large cohort studies from France (n = 60 000 patients) and UK (n = 90 000 patients). These authors showed that the occasional intake of BZ was associated with an increase in mortality. Moreover, data from the American Cancer Society suggest that the combination of insomnia with the intake of hypnotics may be associated with an increased mortality (Kripke, 2009 (Kripke, , 2011 (Kripke, , 2013 Clinical algorithm Figure 1 . Clinical algorithm for the diagnosis and treatment of insomnia. If a patient suffers from sleep onset/sleep maintenance/early morning awakening disturbances and associated daytime impairment, he/she is a candidate for applying this guideline. If the symptoms are not severe enough to qualify for clinically significant impairment, psychoeducative/preventive interventions should be applied (e.g. sleep hygiene). If the symptoms are clinically significant, the clinician, following the diagnostic process outlined in Table 3 , should check for possible circadian underpinnings, substance intake (e.g. alcohol) and somatic and mental co-morbidities. Positive results in any of these areas should lead to corresponding interventions (i.e. insomnia coupled with high intake of alcohol: abstinence from alcohol, etc.). The sequence of treatments (insomnia versus its co-morbidities), i.e. consecutive versus simultaneous, is determined by the clinician. Cognitive behavioural therapy for insomnia (CBT-I) should always be considered as first-line treatment, medications like benzodiazepines (BZ), benzodiazepine receptor agonists (BZRA) or sedating antidepressants are recommended only for short-term use.
ª 2017 European Sleep Research Society et al ., 1979, 2002) . Further research (Frandsen et al., 2014; Jennum et al., 2015 Jennum et al., , 2016 investigated mortality associated with the use of BZ, antidepressants and antipsychotics in patients with Parkinson's disease, dementia and stroke. These studies also showed an increased mortality in those using psychotropic agents.
RECOMMEN DATIONS
Our overall recommendations for the diagnosis and therapy of insomnia are presented in Table 15 . Additionally, a clinical algorithm for the diagnostic and therapeutic process is summarized in Fig. 1 .
Please note that these recommendations largely correspond to the guidelines for insomnia treatment of the American College of Physicians (ACP, 2016) . Both guidelines recommend CBT-I as first-line treatment for insomnia. Concerning the pharmacological treatment of insomnia, an American Academy of Sleep Medicine guideline gave a 'weak' recommendation for orexin receptor antagonists, BZ, BZRAs, doxepine and ramelteon to treat insomnia (Sateia et al., 2017) . Substances like trazodone, tiagabine, diphenhydramine, melatonin, tryptophan and valerian were explicitly not recommended in this guideline.
OU TLOOK FOR TH E FU TURE
Cognitive behavioural therapy for insomnia, though being the first-line treatment for insomnia, is not easily available. It is assumed that only a minority of patients with chronic insomnia will receive this treatment in Europe. Thus, the widespread implementation of CBT-I will be a major challenge for the future. Apart from physicians and clinical psychologists/psychotherapists, other health professionals (e.g. nurses) should be trained in CBT-I. Furthermore, web-based delivery of CBT-I may offer a chance to improve the healthcare situation for patients with insomnia in Europe.
The efficacy of the different components of CBT-I as standalone interventions has been rarely investigated or compared. Thus, more work is necessary to dismantle the effects of these components in randomized controlled studies. In addition, the impact of CBT-I on daytime function in those with insomnia has been scarcely investigated.
With respect to new psychotherapeutic approaches, further research is needed to evaluate mindfulness-based treatments and hypnotherapy. Furthermore, these approaches, in addition to other techniques, should be explored, especially in those who do not respond to traditional CBT-I. For example, one pilot study indicated that Acceptance and Commitment Therapy (ACT; Hertenstein et al., 2014) might be a useful alternative for nonresponders. Another innovative approach consists of intensive sleep retraining (Harris et al., 2012) . This very brief therapeutic approach is realized in the sleep laboratory, and can be utilized over a period of 25 h and is thought to be based on a reconditioning of sleep. The positive effects of a first randomized controlled trial (Harris et al., 2012) also raise questions about the potential of sleep deprivation in the context of insomnia treatment.
With respect to the most frequently used drugs for insomnia, BZ and BZRAs, the question of efficacy and side-effects of long-term treatment should be addressed in naturalistic studies. It would be especially helpful to know before the first prescription, which patient will abuse these substances or become dependent on them.
Newer hypnotic drugs like ramelteon or suvorexant have been introduced into the healthcare system of the USA, but not in Europe. In particular, it remains an open question whether the orexin receptor antagonists will be available on the European market in the near future. Other drugs that are sometimes used for the treatment of insomnia, like tiagabine and pregabalin, have not been subjected to thorough testing concerning their efficacy and side-effects -further research is needed here.
Light therapy and exercise may be useful treatment approaches for insomnia, and it is unlikely that these treatments produce severe side-effects. Light therapy has clear effects on several biological parameters. In this context it is also suggested that further research into circadian underpinnings of insomnia might be helpful to gain new insights into its pathophysiology. However, the efficacy for those with insomnia remains to be seen. Similarly, exercise is a well-established strategy for improving general health. However, whether it has specific effects on insomnia remains unclear.
Very new treatments include brain cooling and electrostimulation. A brain-cooling device has been introduced on to the market in the USA recently (Nofzinger and Buysse, 2011) . Electrostimulation has been shown to induce slowwave sleep in experimental studies, and it has been tested in good sleepers and poor sleepers with mixed effects (Frase et al., 2016 (Frase et al., , 2017 . Further research needs to be conducted and published on the efficacy of these treatments.
